Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 2Lymphoid 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Hematologic Neoplasms 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × ricolinostat × Lymphoid × Clear all
NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

NCT02091063 2024-08-06

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies

Columbia University

Phase 1/2 Terminated
23 enrolled 6 charts
LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡